glp 1 covered by cigna is making GLP-1 coverage a harder sell for employers Why Cigna is capping cost

AOD-9604 is the more-studied stabilized version Compound Human Growth Hormone (somatropin) Class Full-length recombinant hGH FDA Status FDA-approved for specific indications (GH deficiency, certain growth disorders, AIDS wasting) Evidence Strength Strong human evidence for approved indications

Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029

One recent study suggested that women who go on a GLP-1 have an easier time finding a job

100% soluble powder formula with a slight zingy taste

The men are expected to comply with the suggested dosage on the product label or seek advice from a fitness or health professional in order to make the intake more specific to needs